ArticleCancer science2020
CD4
Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- A meta-analysis of experimentally validated neo-epitopes: patterns, biases, and opportunities.Cancer immunology, immunotherapy : CII · 2025Pooled it
- mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients.Frontiers in immunology · 2025Trial
- FlowSpot Enables Decentralized Phenotypic and Functional Cellular Immune Profiling from Dried Blood Spots.bioRxiv : the preprint server for biology · 2026Article
- VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma.Journal for immunotherapy of cancer · 2026Article
- IL-2 Free Expansion of T Cells with Immunofilaments.Advanced healthcare materials · 2026Article
- A novel gene signature based on Like-Smith family members-related genes for predicting the prognosis of hepatocellular carcinoma.Translational cancer research · 2026Article
- Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity.NPJ vaccines · 2026Article
- Review
- Inactivated mycobacterium paragordonae delivered via microneedle patches as a novel tuberculosis booster vaccine.Human vaccines & immunotherapeutics · 2025Article
- Immune profiling identifies CD161Journal of translational medicine · 2025Article
- Quantitative peripheral live single T-cell dynamic polyfunctionality profiling predicts lung cancer checkpoint immunotherapy treatment response and clinical outcomes.Translational lung cancer research · 2024Article
- Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate.PLoS pathogens · 2024Article
- CD4Trends in cancer · 2024Review
- Safety and Immunogenicity Study of a Bivalent Vaccine for Combined Prophylaxis of COVID-19 and Influenza in Non-Human Primates.Vaccines · 2024Article
- A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applications.Molecular therapy. Methods & clinical development · 2024Article
- The role of immune cells and immune related genes in the tumor microenvironment of papillary thyroid cancer and their significance for immunotherapy.Scientific reports · 2024Article
- Article
- Phenotypic and Functional Characterization of Memory CD4Methods in molecular biology (Clifton, N.J.) · 2024Review
- Metabolic reprogramming involves in transition of activated/resting CD4Frontiers in immunology · 2023Article
- The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.BMC cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
Polyfunctionality/multifunctionality of effector T cells at the single cell level has been shown as an important parameter to predict the quality of T cell response and immunological control of infectious disease and malignancy. However, the fate of polyfunctional CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.